A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension

Masaharu Kataoka, Noritoshi Nagaya, Toru Satoh, Takefumi Itoh, Shinsuke Murakami, Takashi Iwase, Yoshinori Miyahara, Shingo Kyotani, Yoshiki Sakai, Kenji Kangawa, Satoshi Ogawa

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Rationale: The balance between prostacyclin and thromboxane plays an important role in the regulation of pulmonary vascular tone. Recently, we developed ONO-1301, a novel, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. Objectives: We investigated whether modulation of prostacyclin/thromboxane balance by ONO-1301 ameliorates monocrotaline-induced pulmonary hypertension in rats. Methods: After subcutaneous injection of monocrotaline or vehicle, rats were randomized to receive repeated subcutaneous administration of ONO-1301 or vehicle twice per day for 3 wk. Measurements and Main Results: There was significant development of pulmonary hypertension 3 wk after monocrotaline injection. Treatment with ONO-1301 significantly attenuated the increases in right ventricular systolic pressure and ratio of right ventricular weight to body weight in monocrotaline rats. Furthermore, ONO-1301 significantly attenuated the increase in medial wall thickness of peripheral pulmonary arteries in monocrotaline rats. The half-life of plasma ONO-1301 concentration after a single subcutaneous administration was approximately 5.6 h. A single administration of ONO-1301 increased plasma cyclic adenosine 3′, 5′-monophosphate level, which lasted at least up to 8 h. Treatment with ONO-1301 significantly decreased plasma 11-dehydro-thromboxane B 2 , a metabolite of thromboxane, in monocrotaline rats. Finally, Kaplan-Meier survival curves demonstrated that repeated administration of ONO-1301 improved survival rate in monocrotaline rats compared with vehicle administration (80 vs. 30% in 6-wk survival). Conclusions: Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cyclic adenosine 3′, 5′-monophosphate and inhibition of thromboxane synthase.

Original languageEnglish
Pages (from-to)1575-1580
Number of pages6
JournalAmerican journal of respiratory and critical care medicine
Volume172
Issue number12
DOIs
Publication statusPublished - 2005 Dec 15
Externally publishedYes

Fingerprint

Thromboxanes
Epoprostenol
Monocrotaline
Pulmonary Hypertension
Adenosine
ONO 1301
Kaplan-Meier Estimate
Ventricular Pressure
Subcutaneous Injections
Pulmonary Artery
Blood Vessels
Half-Life
Body Weight
Blood Pressure
Weights and Measures
Lung

Keywords

  • cAMP
  • Hemodynamics
  • Monocrotaline
  • Vascular remodeling

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. / Kataoka, Masaharu; Nagaya, Noritoshi; Satoh, Toru; Itoh, Takefumi; Murakami, Shinsuke; Iwase, Takashi; Miyahara, Yoshinori; Kyotani, Shingo; Sakai, Yoshiki; Kangawa, Kenji; Ogawa, Satoshi.

In: American journal of respiratory and critical care medicine, Vol. 172, No. 12, 15.12.2005, p. 1575-1580.

Research output: Contribution to journalArticle

Kataoka, M, Nagaya, N, Satoh, T, Itoh, T, Murakami, S, Iwase, T, Miyahara, Y, Kyotani, S, Sakai, Y, Kangawa, K & Ogawa, S 2005, 'A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension', American journal of respiratory and critical care medicine, vol. 172, no. 12, pp. 1575-1580. https://doi.org/10.1164/rccm.200501-102OC
Kataoka, Masaharu ; Nagaya, Noritoshi ; Satoh, Toru ; Itoh, Takefumi ; Murakami, Shinsuke ; Iwase, Takashi ; Miyahara, Yoshinori ; Kyotani, Shingo ; Sakai, Yoshiki ; Kangawa, Kenji ; Ogawa, Satoshi. / A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. In: American journal of respiratory and critical care medicine. 2005 ; Vol. 172, No. 12. pp. 1575-1580.
@article{be8b7604d191418d8776de1060e4d264,
title = "A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension",
abstract = "Rationale: The balance between prostacyclin and thromboxane plays an important role in the regulation of pulmonary vascular tone. Recently, we developed ONO-1301, a novel, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. Objectives: We investigated whether modulation of prostacyclin/thromboxane balance by ONO-1301 ameliorates monocrotaline-induced pulmonary hypertension in rats. Methods: After subcutaneous injection of monocrotaline or vehicle, rats were randomized to receive repeated subcutaneous administration of ONO-1301 or vehicle twice per day for 3 wk. Measurements and Main Results: There was significant development of pulmonary hypertension 3 wk after monocrotaline injection. Treatment with ONO-1301 significantly attenuated the increases in right ventricular systolic pressure and ratio of right ventricular weight to body weight in monocrotaline rats. Furthermore, ONO-1301 significantly attenuated the increase in medial wall thickness of peripheral pulmonary arteries in monocrotaline rats. The half-life of plasma ONO-1301 concentration after a single subcutaneous administration was approximately 5.6 h. A single administration of ONO-1301 increased plasma cyclic adenosine 3′, 5′-monophosphate level, which lasted at least up to 8 h. Treatment with ONO-1301 significantly decreased plasma 11-dehydro-thromboxane B 2 , a metabolite of thromboxane, in monocrotaline rats. Finally, Kaplan-Meier survival curves demonstrated that repeated administration of ONO-1301 improved survival rate in monocrotaline rats compared with vehicle administration (80 vs. 30{\%} in 6-wk survival). Conclusions: Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cyclic adenosine 3′, 5′-monophosphate and inhibition of thromboxane synthase.",
keywords = "cAMP, Hemodynamics, Monocrotaline, Vascular remodeling",
author = "Masaharu Kataoka and Noritoshi Nagaya and Toru Satoh and Takefumi Itoh and Shinsuke Murakami and Takashi Iwase and Yoshinori Miyahara and Shingo Kyotani and Yoshiki Sakai and Kenji Kangawa and Satoshi Ogawa",
year = "2005",
month = "12",
day = "15",
doi = "10.1164/rccm.200501-102OC",
language = "English",
volume = "172",
pages = "1575--1580",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "12",

}

TY - JOUR

T1 - A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension

AU - Kataoka, Masaharu

AU - Nagaya, Noritoshi

AU - Satoh, Toru

AU - Itoh, Takefumi

AU - Murakami, Shinsuke

AU - Iwase, Takashi

AU - Miyahara, Yoshinori

AU - Kyotani, Shingo

AU - Sakai, Yoshiki

AU - Kangawa, Kenji

AU - Ogawa, Satoshi

PY - 2005/12/15

Y1 - 2005/12/15

N2 - Rationale: The balance between prostacyclin and thromboxane plays an important role in the regulation of pulmonary vascular tone. Recently, we developed ONO-1301, a novel, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. Objectives: We investigated whether modulation of prostacyclin/thromboxane balance by ONO-1301 ameliorates monocrotaline-induced pulmonary hypertension in rats. Methods: After subcutaneous injection of monocrotaline or vehicle, rats were randomized to receive repeated subcutaneous administration of ONO-1301 or vehicle twice per day for 3 wk. Measurements and Main Results: There was significant development of pulmonary hypertension 3 wk after monocrotaline injection. Treatment with ONO-1301 significantly attenuated the increases in right ventricular systolic pressure and ratio of right ventricular weight to body weight in monocrotaline rats. Furthermore, ONO-1301 significantly attenuated the increase in medial wall thickness of peripheral pulmonary arteries in monocrotaline rats. The half-life of plasma ONO-1301 concentration after a single subcutaneous administration was approximately 5.6 h. A single administration of ONO-1301 increased plasma cyclic adenosine 3′, 5′-monophosphate level, which lasted at least up to 8 h. Treatment with ONO-1301 significantly decreased plasma 11-dehydro-thromboxane B 2 , a metabolite of thromboxane, in monocrotaline rats. Finally, Kaplan-Meier survival curves demonstrated that repeated administration of ONO-1301 improved survival rate in monocrotaline rats compared with vehicle administration (80 vs. 30% in 6-wk survival). Conclusions: Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cyclic adenosine 3′, 5′-monophosphate and inhibition of thromboxane synthase.

AB - Rationale: The balance between prostacyclin and thromboxane plays an important role in the regulation of pulmonary vascular tone. Recently, we developed ONO-1301, a novel, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. Objectives: We investigated whether modulation of prostacyclin/thromboxane balance by ONO-1301 ameliorates monocrotaline-induced pulmonary hypertension in rats. Methods: After subcutaneous injection of monocrotaline or vehicle, rats were randomized to receive repeated subcutaneous administration of ONO-1301 or vehicle twice per day for 3 wk. Measurements and Main Results: There was significant development of pulmonary hypertension 3 wk after monocrotaline injection. Treatment with ONO-1301 significantly attenuated the increases in right ventricular systolic pressure and ratio of right ventricular weight to body weight in monocrotaline rats. Furthermore, ONO-1301 significantly attenuated the increase in medial wall thickness of peripheral pulmonary arteries in monocrotaline rats. The half-life of plasma ONO-1301 concentration after a single subcutaneous administration was approximately 5.6 h. A single administration of ONO-1301 increased plasma cyclic adenosine 3′, 5′-monophosphate level, which lasted at least up to 8 h. Treatment with ONO-1301 significantly decreased plasma 11-dehydro-thromboxane B 2 , a metabolite of thromboxane, in monocrotaline rats. Finally, Kaplan-Meier survival curves demonstrated that repeated administration of ONO-1301 improved survival rate in monocrotaline rats compared with vehicle administration (80 vs. 30% in 6-wk survival). Conclusions: Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cyclic adenosine 3′, 5′-monophosphate and inhibition of thromboxane synthase.

KW - cAMP

KW - Hemodynamics

KW - Monocrotaline

KW - Vascular remodeling

UR - http://www.scopus.com/inward/record.url?scp=30444453849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444453849&partnerID=8YFLogxK

U2 - 10.1164/rccm.200501-102OC

DO - 10.1164/rccm.200501-102OC

M3 - Article

C2 - 16192456

AN - SCOPUS:30444453849

VL - 172

SP - 1575

EP - 1580

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 12

ER -